tasisulam + temozolomide

**Tasisulam + temozolomide** is an investigational combination therapy involving tasisulam, an intravenously administered, highly albumin-bound small molecule with complex, not fully elucidated antineoplastic pharmacology, and temozolomide, an oral alkylating agent that induces cytotoxic DNA methylation. Tasisulam has exhibited activity across several tumor types when combined with standard chemotherapies, while temozolomide is FDA-approved for glioblastoma and anaplastic astrocytoma and is commonly used in other gliomas. The combination has been explored in advanced solid tumors in phase 1b studies to define safety, pharmacokinetics, and potential efficacy, with primary dose-limiting toxicities in hematologic parameters such as neutropenia and thrombocytopenia.

Brand names

Temomedac

Other names

tasisulam sodiumTMZtasisulam + temozolomide